A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Subjects With Osteomyelitis Known or Suspected to be Due to Gram- Positive Organisms
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Dalbavancin (Primary)
- Indications Osteomyelitis
- Focus Therapeutic Use
- Sponsors Durata Therapeutics
- 06 Aug 2017 Planned End Date changed from 1 Nov 2017 to 23 Dec 2017.
- 06 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 23 Dec 2017.
- 06 Aug 2017 Status changed from recruiting to active, no longer recruiting.